Blueprint Medicines (BPMC) 2024 Wells Fargo Healthcare Conference summary

Business performance and financial outlook

• 2024 is tracking as a strong year, with projected revenue of $435–450 million, driven by the Ayvakit launch in ISM and robust portfolio progress, especially BLU-808.

• Financial health is strong, with disciplined capital allocation and a clear path to sustainability, supported by growing US and international revenues.

• Guidance has been raised twice in 2024 due to stronger-than-expected business performance, particularly in patient growth and therapy duration.

• Price negotiations in Germany are ongoing, with a conservative approach to revenue recognition for the second half of the year.

• Capital allocation priorities are focused on Ayvakit, its lifecycle management, and advancing BLU-808, with resources aligned accordingly.

Ayvakit launch and market dynamics

• Ayvakit is the first approved therapy for indolent systemic mastocytosis, with strong and steady patient growth and low discontinuation rates.

• Revenue growth benefited from a decrease in patients on free goods, driven by a more commercial payer mix and improved affordability from the Inflation Reduction Act.

• International pricing, especially in Germany, is being closely monitored, with potential 30–50% price reductions factored into guidance.

• Duration of therapy is trending multi-year, with advanced SM patients averaging 25 months, supporting long-term revenue potential.

• Patient and provider activation are key growth drivers, with a focus on the 9,500 diagnosed but inadequately managed SM patients and expanding prescriber confidence through new data.

Growth strategy and future opportunities

• The addressable market is expanding, with over 20,000 diagnosed SM patients and about half inadequately managed, offering significant room for growth.

• Long-term safety and efficacy data from the Pioneer study are lowering prescriber thresholds and increasing adoption.

• Seasonality affects timing of therapy starts but not overall demand, with strong compliance observed for the oral therapy.

• The path to $2 billion+ in peak sales is supported by increasing breadth and depth of prescribing, long therapy durations, and ongoing evidence generation.

• Competitive landscape is acknowledged, with plans to innovate further through next-generation programs like Elenestinib, aiming for differentiated labels and broader impact.